https://en.m.wikipedia.org/wiki/Osemozotan
Osemozotan (MKC-242) is a selective 5-HT1A receptor agonist with some functional selectivity, acting as a full agonist at presynaptic and a partial agonist at postsynaptic 5-HT1A receptors.
https://www.ncbi.nlm.nih.gov/m/pubmed/11208912/The target of Osemozotan is 5-HT1A receptors. This molecules bind with almost 1000 times greater affinity to 5-HT1A receptors than most other 5-HT, dopamine, or adrenergic receptors.[2] With repeated exposure of Osemozotan at the 5-HT1A receptors, there seems to be no change in the number of receptors, which is not typically seen with pharmaceutical agonists.
https://pubchem.ncbi.nlm.nih.gov/compou ... n=WIPO-IPCAcute citalopram (3 and 30 mg/kg) treatment together with subchronic lithium treatment showed significant increases in the extracellular 5-HT concentrations, compared with citalopram treatment alone. Acute MKC-242 (1 mg/kg) treatment showed significant decreases in extracellular 5-HT concentrations, in both the normal diet and lithium diet groups to the same extent.